Evidence map›Paper›PMID 40450287›Full record

ArticleBMC cancer2025

Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.

Kewei Du, Wenfei Hu, Shan Gao, Jianxin Gan, Chongge You, Shangdi Zhang

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Research progress of machine learning applications in gastric cancer diagnosis and therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kewei DuLaboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Wenfei HuLaboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Shan GaoLaboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Jianxin GanDepartment of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Chongge You *Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China. youchg@lzu.edu.cn.
Shangdi Zhang *Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China. zhangsd1985@126.com.

Funding

Gansu Province Health Industry Scientific Research Project GSWSKY2023-03National Natural Science Foundation of China 32060231
6 · The paper itself

Abstract

backgroundGastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with early diagnosis remaining a significant challenge. Available serum biomarkers lack specificity, making it difficult to accurately identify early non-metastatic GC cases. Reliable diagnostic biomarkers that can detect early GC are critical to improve prognosis.

methodsWe employed serum proteomics combined with bioinformatics to identify genes differentially expressed in the serum of non-metastatic GC patients. Single-cell RNA sequencing (ScRNA-seq) and immune infiltration analysis were performed to evaluate the relationship between gene expression and immune cell function. Then we evaluated 107 machine learning models for biomarker-based early GC diagnosis and develops a nomogram validated for accuracy and clinical utility, subsequently comparing the performance of potential biomarkers with traditional tumor markers in diagnosing early gastric cancer. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) and immunohistochemical staining using the Human Protein Atlas (HPA) database were used to validate the differential expression of candidate genes in GC tissues and adjacent non-cancerous tissues.

resultsThe proteomic analysis identified several genes upregulated in the serum of GC patients compared to healthy controls. Single-cell RNA sequencing analysis further revealed that these upregulated genes were associated with altered immune cell infiltration in the tumor microenvironment. The glmBoost + XGBoost model incorporating B2M, CFL1, CTSD, and HSP90AB1 demonstrated strong diagnostic performance (mean AUC = 0.792), with 101 algorithm combinations achieving an average AUC > 0.7. A nomogram integrating gene expression and clinical data was developed, validated through calibration and decision curve analyses, highlighting its potential for early GC diagnosis. Additionally, four genes—TAGLN2, HSP90AB1, SH3BGRL3, and CFL1—were found to be highly expressed in non-metastatic GC tissues and were significantly correlated with immune infiltration, including CD8 + T cells, monocytes, and myeloid-derived suppressor cells. These findings were validated by qRT-PCR and immunohistochemical analyses, confirming their elevated expression in GC tissues.

conclusionsTAGLN2, HSP90AB1, SH3BGRL3 and CFL1 are potential diagnostic biomarkers for early-stage GC, with strong associations with immune cell infiltration. Machine learning model shows excellent diagnostic performance. These results provide a foundation for future studies to improve early diagnosis and individualized treatment strategies for GC.

Indexed as

Biomarkers, TumorMachine LearningStomach NeoplasmsEarly Detection of CancerFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMultiomicsNomogramsPrognosisProteomicsTumor MicroenvironmentBiomarkers, TumorDiagnostic modelGastric cancerImmune infiltrationMachine learningProteomicsSingle-cell RNA sequencing

Identifiers

PMID40450287
PMCPMC12126892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.